tirzepatide pregnancy safety guidance studies Is Safe While Breastfeeding? FDA & Alternatives tirzepatide pregnancy safety when to – Can the new diabetes and – Tirzepatide and Pregnancy: Safety, Risks,

While both types of activities can improve mood temporarily, only effortful activities support sustainable motivation improvement through appropriate dopamine signaling

Whats also interesting about these drugs is that GLP-1 is a neuropeptide

The FDA has also approved Wegovy for adolescents aged 12 years and older who have obesity, defined as: a BMI at or above the 95th percentile for age and sex, based on CDC growth charts Must weigh at least 60 kg (132 lbs) Administered as a once-weekly subcutaneous injection Must be used in conjunction with a reduced-calorie diet and increased physical activity If an adolescent does not achieve at least a 5% reduction in BMI after 12 weeks on the 2.4 mg or maximum tolerated dose, treatment should be discontinued and re-evaluated In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, stroke, and heart attack in adults with cardiovascular disease and either obesity or overweight

Remember that weight management is complex and multifactorialopen communication with your healthcare team is essential for optimizing your treatment outcomes and addressing any underlying issues that may be affecting your response to tirzepatide

Your first step is to call your doctor immediately